Cabotegravir Injectable Depot
The cabotegravir injectable depot developed by CONRAD is a high priority, long-acting, low-cost, biodegradable silica hydrogel injectable depot product that provides a similar active pharmaceutical ingredients dose to the clinically tested cabotegravir long-acting nanosuspension in a smaller volume (~1 mL), subcutaneous (less painful), lasting 2-3-fold longer (4-6 months duration), with potential for a shorter pharmacokinetics tail.
Cabotegravir Injectable Depot with Levonorgestrel
The cabotegravir injectable depot with levonorgestrel product is a long-acting, biodegradable silica hydrogel injectable depot that delivers two approved active pharmaceutical ingredients with established safety and efficacy, Cabotegravir, for HIV prevention, and Levonorgestrel, for contraception.
Cabotegravir Pellet Implant
The cabotegravir pellet implant developed by CONRAD is a high priority, low-cost pellet-based subdermal implant system with customized inserter for rapid, safe, and low-cost use by minimally trained health care providers that may provide prophylactic levels of cabotegravir for up to 9-12 months. This implant can be removed, if needed, with the active pharmaceutical ingredient having a potentially shorter pharmacokinetics tail.
Cabotegravir Pellet Implant with Levonorgestrel
The cabotegravir pellet implant with levonorgestrel is a long-acting multipurpose prevention technology implantable product combining cabotegravir, for HIV prevention, and levonorgestrel, for contraception, in a biodegradable subdermal pellet system. This product is a low-cost, biodegradable subdermal pellet-type implant system that provides tightly controlled, long-acting sustained release of its payload, is highly tunable, and does not require surgical removal.
Extended Release Dapivirine Vaginal Film
The Dapivirine extended-release monthly film, being developed by the Rohan Pharmaceutics laboratory at the University of Pittsburgh School of Pharmacy and Magee-Womens Research Institute under the VALUE (Vaginal film as A Low-cost, User-administered, and Extended-release product) project, is a game-changing female-controlled product providing monthly protection against HIV infection. The film is simple, portable, discreet, applicator-free, scalable, low cost, and bioerodible, with minimal package waste.
Extended Release Dapivirine Vaginal Film with Levonorgestrel
The multipurpose prevention technology (MPT) vaginal film being developed by the Rohan Pharmaceutics laboratory at the University of Pittsburgh School of Pharmacy and Magee-Womens Research Institute is a product providing monthly protection against HIV acquisition and unintended pregnancy. Building upon our innovative bioerodible vaginal film platform, this MPT product is being developed as a convenient, low-cost option with desirable features that are informed through end-user acceptability research.
Griffithsin Fast Dissolving Vaginal Insert
The Griffithsin (GRFT) fast-dissolving insert (FDI) is developed by Population Council. This fast-dissolving vaginal insert is an on-demand HIV prevention product for women and girls, including pregnant and breastfeeding women, designed for over-the-counter distribution as a non-antiretroviral option.
Non-ARV/Non-Hormonal Multi-Purpose Vaginal Ring
The non-antiretroviral, non-hormonal intravaginal ring developed by the Oak Crest Institute of Science is a multipurpose prevention technology with a 1-to 3-month duration combining two novel, luminally acting active pharmaceutical ingredients: (1) an anti-viral with unique mechanisms of action against HIV, HSV, and HPV; and (2) a contraceptive and would be a game-changer product for women who desire non-hormonal contraceptives with prevention of HIV and other sexually transmitted infections in a single product.
TAF/EVG Fast Dissolving Vaginal Insert
The Tenofovir alafenamide/ Elvitegravir (TAF/EVG) Fast Dissolving Insert is developed by CONRAD. After extensive end-user research, a TAF/EVG dual-compartment insert for PrEP or PEP user-controlled, on-demand use and Multipurpose Prevention Technology against HIV and HSV, will be advanced clinically, providing a user-friendly on-demand product.